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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: This study investigated the clinical significance of quality of life (QOL)
related specifically to Graves’ ophthalmopathy (GO) among Taiwanese patients.
Methods: We recruited 271 patients with GO who were seen at the National Taiwan University
Hospital Department of Ophthalmology from September 1, 2012 to November 30, 2012.
Patients completed the GO-QOL Questionnaire. The main outcome measures were the scores
on two GO-QOL subscales: visual functioning and appearance. The percentage of responses
occurring at the maximum and minimum values was also calculated to assess possible ceiling
and floor effects, respectively.
Results: The mean  standard deviation QOL scores for the subscales of visual functioning and
appearance were 58.39  25.17 and 54.45  20.52, respectively. The scores for both subscales
were significantly correlated with disease severity and clinical activity scores (all p < 0.05).
The QOL scores for the appearance subscale were significantly correlated with the degree
of diplopia (p < 0.05). No significant ceiling or floor effects were observed for either subscale
of the GO-QOL.
Conclusion: Scores on the Chinese (Taiwan) version of the GO-QOL were strongly correlated
with disease severity and clinical activity. The GO-QOL is a simple and practical tool that
can be used to evaluate health-related QOL in GO patients.
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Table 1 Components of the clinical activity score for
Graves’ ophthalmopathy (GO).a
 Spontaneous retrobulbar pain
 Pain with eye movement
 Redness of the eyelids
 Redness of the conjunctiva
 Swelling of the eyelids
 Swelling of the caruncle
 Conjunctival edema (chemosis)
a The clinical activity score is calculated according to the
presence or absence of the characteristics listed. The score
ranges from 0 to 7, with 0e2 characteristics indicating inactive
GO and 3e7 characteristics indicating active GO.
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Graves’ ophthalmopathy (GO) is a chronic, debilitating
infiltrative eye disease that is often associated with Graves’
disease or occasionally with Hashimoto’s thyroiditis.
Approximately 50% of patients with Graves’ disease develop
GO, and those patients often suffer from ocular pain,
changed appearance, and impaired visual function.1 The
severity of GO can be quantified using various clinical
measures, including tests of optic nerve function or mea-
surements of proptosis and strabismus. However, these
clinical parameters fail to quantify several of the most
troublesome features of GO, such as altered appearance
and ocular pain symptoms.
The GO-Quality of Life Questionnaire (GO-QOL), created
by Terwee et al,2 was the first instrument designed spe-
cifically to measure health-related QOL in patients with
GO. The questionnaire consists of 16 questions focusing on
two specific consequences of GO-visual impairment: (1)
double vision or decreased visual acuity (8 questions); and
(2) psychosocial effects of facial disfigurement (8 ques-
tions). Scores on the GO-QOL have shown strong correla-
tions with clinical manifestations of GO and with two other
health-related QOL questionnaires (Medical Outcome Study
24-item Short Form Health Survey and Sickness Impact
Profile).2e5 The GO-QOL was originally developed in Dutch,
but has been translated into several languages and used
in various countries.6e10 An increasing number of studies
have used GO-QOL score as one of several outcome mea-
sures to evaluate treatment effects.7,8,11,12 For this study,
we translated the GO-specific QOL survey into traditional
Chinese and used the questionnaire with a group of GO
patients in Taiwan (Appendix 1). The purpose of our study
was to assess the QOL of Taiwanese patients with GO and to
evaluate the correlations between the severity of the dis-
ease and QOL scores.
Materials and methods
We downloaded the English version of the GO-QOL from the
European Group on Graves’ Orbitopathy (EUGOGO) web-
site13 and translated the GO-QOL into Chinese. The ques-
tionnaire was scored as described by Terwee et al.2 This
QOL instrument was specifically designed for GO patients
and should not be used to assess patients with unrelated
health conditions.
We recruited patients with GO who were seen at the
National Taiwan University Hospital Department of
Ophthalmology (Taipei, Taiwan) between September 1,
2012 to November 30, 2012. The study group included 271
consecutive patients with GO. To be eligible for the survey,
patients were required to have thyroid function tests with
the reference range prior to and within 6 months at the
time of completing the survey. Clinical data were obtained
retrospectively from the medical records. From the survey,
45 patients (16.6%) had received orbital decompression
prior to completing the survey. This study was approved by
the National Taiwan University Committee, and informed
consent was obtained from all participants.All patients completed the GO-QOL during their outpa-
tient clinic consultation. The majority of the questionnaires
were completed without assistance, but explanations of
questions were provided by study personnel if requested by
a patient. The Chinese GO-QOL contained 16 items focusing
on two specific consequences of GO-visual impairment: (1)
limitations in carrying out daily activities; and (2) psycho-
social consequences related to thyroid eye disease. Each
item was scored on a 3-point scale (1 Z severely limited;
2 Z a little limited; 3 Z not limited at all). The responses
for Items 1e8 and for Items 9e16 were summed to yield
2 raw scores. The possible values for these scores ranged
from 8 to 24. The raw scores were then transformed to
2 scores from 0 to 100 using the following formula: (total
scores e #) / (2  #) 100, where # represents the number
of completed items. For both scores, 0 indicated the worst
possible health state, and 100 indicated the best possible
health state. When a participant responded that he or she
did not perform an activity for any reason, the response
was scored as missing, as described in the GO-QOL scoring
algorithm.
Patients also received a complete ophthalmic assess-
ment, including proptosis measurement, lid retraction,
extraocular muscle involvement, and optic neuropathy.
Proptosis was measured by Hertel exophthalmometry. The
degree of diplopia was assessed objectively by the Worth
four dots test, and subjectively by the Gorman scale, with
scores being as follows: Grade 0, no diplopia; Grade 1,
intermittent; Grade 2, inconstant (gaze evoked); and Grade
3, constant diplopia in primary gaze or while reading.14
Optic neuropathy was defined as the presence of disc
swelling or pallor, plus any one of the following: (1) a visual
field defect detected by Humphrey visual field testing, in
the absence of other ocular comorbidity for visual field
defect; (2) relative afferent papillary defect in the absence
of other ocular comorbidity; and (3) Snellen visual
acuity < 20/60, in the absence of other reasons for sight
loss.
Inflammatory activity was represented using the clinical
activity score, which is based on seven signs of inflamma-
tion of the orbit. Each item was scored as absent (0) or
present (1), with a maximum possible score of 7, and total
possible scores ranging from 0 to 7. Scores of 0e2 indicated
Table 2 Demographics and clinical characteristics of
Graves’ ophthalmopathy (GO) patients (n Z 271).
n %
Female/male 192/79 70.8/29.1
Age, median (range), y 42.3 (14e85)
Clinical severity
Mild 148 54.61
Moderate to severe 97 35.62
Sight-threatening 26 9.96
Diplopia
No diplopia 202 74.54
Intermittent diplopia 49 18.08
Inconstant diplopia 15 5.54
Constant diplopia 5 1.85
Clinical activity score
Inactive GO 217 80.1
Active GO 54 19.9
Proptosis, median (range), mm 18.2 (12e28)
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(Table 1).
The clinical severity of GO was scored according to the
NOSPECS system [no signs or symptoms; only signs; soft
tissue involvement (edema of conjunctivae and lids,
conjunctival injection); proptosis; extraocular muscle
involvement; corneal involvement; sight loss] as recom-
mended by EUGOGO.16 According to a study by Tsai et al,17
the mean Hertel value for exophthalmos was 13.91 mm in a
normal Taiwanese population. We thus selected 14 mm as
the Hertel value for normal exophthalmos. The severity of
soft tissue involvement was scored using a modified
EUGOGO case record form and the Color Atlas.16 Mild GO
was defined as any one of the following: minor lid retrac-
tion (<2 mm); mild soft tissue involvement; proptosis
<17 mm (<3 mm above the normal for race and sex);
transient (Gorman score 1) or no (Gorman score 0) diplopia;
and conservatively treatable corneal exposure. Moderate to
severe GO was defined as any one of the following: lid
retraction of 2 mm; moderate or severe soft tissue
involvement; proptosis of 17 mm (3 mm above the
normal, adjusted for race and sex); or inconstant (Gorman
score 2) or constant (Gorman score 3) diplopia. Sight-
threatening GO was defined as dysthyroid optic neuropa-
thy or corneal breakdown. Patients with a history of optic
neuropathy but without optic neuropathy at the time of this
study were included in the moderate to severe group. Each
patient’s clinical measurements and disease activity were
evaluated by a single ophthalmologist (S.L.L.).
In the statistical analysis, the distribution of continuous
variables is expressed as the mean  standard deviation.
The results for categorical variables are presented as fre-
quencies and percentages. We also calculated the per-
centage of patients scoring 0 or 100 on both subscales of
the GO-QOL to measure the floor and ceiling effects. No
firm benchmarks for determining a significant ceiling effect
have been widely accepted, although this effect has been
described as 20e25% of a respondent group scoring the
maximum possible value.18,19 An excessive ceiling effect
has been reported as >50% of respondents scoring the
maximum possible score or category.20 Bradley et al19 used
the National Eye Institute Visual Function Questionnaire
(NEI VFQ-25) to evaluate the QOL of patients with GO. They
defined “significant” ceiling effects as >15%, and “sub-
stantial” ceiling effects as >30% of respondents attaining
the maximum possible value for each subscale. Similarly,
significant and substantial floor effects were defined as
>15% and >30%, respectively, of responses falling at the
minimum value for a subscale.19 We accepted this defini-
tion in our study because the conditions studied by Bradley
et al19 appeared similar to ours.
The statistical analyses were conducted using R 2.11.1
software (R Foundation for Statistical Computing, Vienna,
Austria). Multiple logistic regression and linear regression
were used to analyze the relationship between indepen-
dent and dependent variables. Independent variables were
factors influencing the GO-QOL score, such as disease
severity or activity, and the dependent variables were the
two GO-QOL subscale scores, appearance and visual func-
tioning. Analyses were performed to assess which of theindependent variables were or were not related to the
dependent variables. Basic model-fitting techniques for
regression analysis were applied to ensure the quality of
the analysis results. In the stepwise variable selection
procedure, both significance level for entry and significance
level for stay were set to 0.15. The coefficient of deter-
mination (R2) represents the square of the Pearson corre-
lation coefficient for the observed versus predicted value of
a continuous response variable in a linear regression model.
A larger value of R2 indicates a better fit of the linear
regression model. The “percentage of concordant pairs” is
the percentage of the “concordant” pairs, in which the
observation with the event (i.e., the observed binary
response is 1) has the higher predicted event probability,
among the total number of the pairs of observations with
different response values (e.g., 0 vs. 1). It has a value be-
tween 0% and 100% with a larger value indicating a better fit
of the logistic regression model to the observed binary
data.
For all statistical analyses in this study, a two-sided
p  0.05 was considered statistically significant. Covariates
with borderline significant p values would still be included
in the final fitted multiple linear or logistic regression
models.Results
Demographic data for all patients are shown in Table 2.
Most of our patients were women, and more than half had a
mild severity of GO. Nearly a quarter of the patient expe-
rienced diplopia. The frequencies of responses to each item
of GO-QOL are summarized in Table 3. All patients who
were given the GO-QOL completed it (100% response rate).
The most frequently limited activities were reading
(81.9%), doing something they wanted to do (87.1%), doing
hobbies or pastimes (68.2%), watching television (63.5%),
Table 3 Frequencies of responses to items on the visual functioning subscale and appearance subscale (n Z 271).
Limitations in carrying out the following activities Severely limited Mildly limited Not limited Missing response
1. Bicycling 11.1 39.9 31.7 17.3a
2. Driving 15.5 33.6 28.4 22.5a
3. Moving around the house 16.6 26.2 57.2 0.0
4. Walking outdoors 17.7 45.0 37.3 0.0
5. Reading 22.9 59.0 18.1 0.0
6. Watching TV 8.1 55.4 36.5 0.0
7. Hobbies or pastimes 14.8 53.4 32.8 0.0
8. Hindered from doing something you wanted to do 17.0 70.1 12.9 0.0
Psychosocial consequences because of
thyroid eye disease
Very much A little No Missing response
1. Appearance has changed 45.0 46.5 8.5 0.0
2. Stared at in the streets 35.4 56.5 8.1 0.0
3. People react unpleasantly 25.5 31.4 43.2 0.0
4. Influence on self-confidence 32.5 42.8 24.7 0.0
5. Socially isolated 4.1 31.0 64.9 0.0
6. Influence on making friends 3.7 63.5 32.8 0.0
7. Appear less often in photos than before 29.2 52.8 18.1 0.0
8. Mask changes in your appearance 14.8 43.2 42.1 0.0
Data are presented as %.
a “Never learned to ride a bike” and “no driver’s license” were scored as missing responses.
Table 4 Results of univariate analysis.
Covariate Visual functioning P* Appearance p*
Sex 0.6067 0.0253
Male 59.27  23.86 51.9  20.16
Female 57.47  26.53 57.1  20.63
Diplopia 0.3227a <0.0001c
No diplopia 60.02  25.40 59.13  18.69
Intermittent diplopia 53.27  24.59 40.18  19.81
Inconstant diplopia 54.59  25.14 43.33  19.69
Constant diplopia 53.75  18.54 38.75  20.44
Severity 0.0062b 0.0001d
Mild 61.78  24.90 58.99  19.95
Moderate to severe 56.69  25.75 50.26  20.22
Sight-threatening 45.78  20.31 44.44  18.45
Clinical activity <0.0001 0.0134
Inactive 61.52  25.17 55.90  20.67
Active 45.78  21.10 48.61  18.95
*Wilcoxon rank-sum test or KruskaleWallis rank-sum test.
a No diplopia versus intermittent diplopia, pZ 0.0915; no diplopia versus inconstant diplopia, pZ 0.4063; no diplopia versus constant
diplopia, p Z 0.5396; intermittent diplopia versus inconstant diplopia, p Z 0.9873; intermittent diplopia versus constant diplopia
p Z 0.8809; and inconstant diplopia versus constant diplopia, p Z 0.9651 (Bonferroni adjusted a Z 0.05/6 Z 0.0083).
b Severity: mild versus moderate to severe p Z 0.1402, mild versus sight-threatening, p Z 0.0018; and moderate to severe versus
sight-threatening, p Z 0.0440 (Bonferroni adjusted a Z 0.05/3 Z 0.0167).
c No diplopia versus intermittent diplopia, p < 0.0001; no diplopia versus inconstant diplopia, pZ 0.0054; no diplopia versus constant
diplopia, p Z 0.0363; intermittent diplopia versus inconstant diplopia, p Z 0.4713; intermittent diplopia versus constant diplopia,
p Z 0.8680; and inconstant diplopia versus constant diplopia, p Z 0.5977 (Bonferroni adjusted a Z 0.05/6 Z 0.0083).
d Severity: mild versus moderate to severe, p Z 0.0009; mild versus sight-threatening, p Z 0.0006; and moderate to severe versus
sight-threatening, p Z 0.2229 (Bonferroni adjusted a Z 0.05/3 Z 0.0167).
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Table 5 Multivariate analysis of the predictors of visual functioning: multiple linear regression with stepwise variable
selection.a
Covariate Regression coefficient Standard error t p
Intercept 79.2055 6.4671 12.247 <0.0001
Clinical activity
Active versus inactive 12.3460 3.7136 3.325 0.0010
Severity 6.3614 2.1859 2.910 0.0039
Age (y) 0.3093 0.1123 2.753 0.0063
Diplopia
No diplopia versus diplopia 6.1986 3.3512 1.850 0.0655
a Multiple linear regression model: n Z 271, R2 Z 0.1205.
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an altered appearance (91.5%) and being stared at in the
streets (91.9%). The GO-QOL scores for the visual func-
tioning and appearance subscales were 58.39  25.17 and
54.45  20.52, respectively. Table 4 shows the results of
the univariate analysis.
Visual functioning subscale
The GO-QOL visual functioning subscale scores were closely
correlated with disease severity (p Z 0.006) and clinical
activity (p < 0.0001). Significant differences emerged for
visual functioning scores between patients with mild versus
sight-threatening GO (p Z 0.0018) and between patients
with moderate-to-severe versus sight-threatening GO
(p Z 0.0440). The difference between patients with mild
versus moderate-to-severe GO was not significant
(p Z 0.1402). Patients with active disease attained mark-
edly lower visual functioning scores (45.78  21.10),
compared with patients who had inactive disease
(61.52  25.17), and the difference was highly significant
(p < 0.0001). However, no correlation was found between
visual functioning and sex (p Z 0.61) or diplopia score
(p Z 0.32).
Multivariate analysis was performed by using a linear
regression model (Table 5). The clinical activity
(p Z 0.001), disease severity (p Z 0.0039), and age
(p Z 0.0063) were the risk factors. No significant ceiling
effect was found for the visual function subscale, with only
14 (5.16%) of the patients scoring the highest possible value
across items. We also found no floor effects because noTable 6 Multivariate analysis of the predictors of appearanc
selection.a
Covariate Regression coefficient
Intercept 96.1862
No diplopia versus diplopia 15.0517
Severity 4.0901
Clinical activity score 1.6758
25 age <55 y 4.8876
Male 4.2227
a Multiple linear regression model: n Z 271, R2 Z 0.32730.patients responded at the lowest possible values across
items.Appearance subscale
The GO-QOL appearance score was closely correlated with
the degree of diplopia (p < 0.0001), disease severity
(p Z 0.0001), clinical activity (p Z 0.0134), and sex
(p Z 0.0253). Male patients attained a significantly lower
appearance score (51.9  20.16) than female patients
(57.1  20.63, p Z 0.0253). In addition, a statistically sig-
nificant difference was found for appearance score be-
tween patients without diplopia and all types of diplopia;
intermittent diplopia (p < 0.0001), inconstant diplopia
(p Z 0.0054), and constant diplopia (p Z 0.0363).
Appearance scores were also correlated with clinical
activity and disease severity. Patients with inactive disease
attained a higher mean appearance score (55.90  20.67)
compared with patients who had active disease
(48.61  18.95, p Z 0.01). The differences of appearance
scores were significant between patients with mild
versus moderate-to-severe GO (p Z 0.0009), and sight-
threatening GO (p Z 0.0006). Multivariate analysis of
the appearance scores was performed using a linear
regression model. Stepwise regression showed that diplopia
(p < 0.0001), disease severity (p Z 0.0125), and clinical
activity (pZ 0.0054) were sufficient to predict appearance
scores (Table 6). No significant ceiling effect emerged for
appearance scores, with only one patient scoring at the
highest possible value across items. In addition, no floore: multiple linear regression model with stepwise variable
Standard error t p
7.4283 12.949 <0.0001
2.4297 6.195 <0.0001
1.6261 2.515 0.0125
0.5971 2.807 0.0054
2.476 1.974 0.0494
2.1648 1.951 0.0522
1052 I.-C. Lin et al.effects were noted because no patient responded at the
lowest value across items.
Discussion
The results of this study suggest that our Chinese (Taiwan)
version of GO-QOL was a valid instrument for evaluating
patients with GO. The participants were patients with GO
of varying degrees of severity and activity. The results
showed that the GO-QOL scores correlated strongly with
the measures of disease severity and clinical activity, and
complemented the objective ophthalmic findings. Our
study also showed that Taiwanese patients with GO, espe-
cially those with active or severe disease, felt markedly
restricted in their daily activities and experienced impaired
self-confidence.
Measures of disease severity and clinical activity
correlated with both subscale scores, visual functioning,
and appearance. These results were similar to those re-
ported in previous studies.9,10 The assessment of disease
severity included many signs and symptoms. The degree of
lid retraction and proptosis may correlate with the
appearance scores. Corneal ulceration and optic neurop-
athy, which are the most severe manifestations of GO,
may have the greatest effect on visual functioning. The
clinical activity score is well known and currently used as a
clinical parameter of disease activity. When patients are
in the active phase of GO, the inflammatory symptoms and
signs such as swelling of the periorbital area, injection of
the eye ball, and retroorbital pain associated with eye
movement can have a negative influence on appearance
and also may impair visual function. Perception of
appearance and decreased visual function makes patients
nervous and depressed and deteriorates their psychosocial
wellbeing.
The degree of diplopia was strongly correlated with
appearance scores, but not with visual functioning scores,
in both univariate and multivariate analyses in this study.
However, our result differed from those of previous studies,
which reported that the degree of diplopia was correlated
only with visual functioning.9,10 We proposed that patients
with diplopia might encounter psychosocial problems
because strabismus renders such people disfigured; in turn,
this may affect their self-confidence.
Male patients attained lower appearance scores,
compared with female patients. This result differed from
the findings of Ponto et al.9 We speculate that among
Taiwanese people, self-confidence might be even more
important for men than it is for women. In addition,
multivariate analysis showed that patients aged 25e55
years attained lower appearance scores than those older
than 55 years. It seems reasonable to conclude thatpatients who would usually be more socially active, such as
younger adults, experience a greater negative effect of GO
on their appearance and emotional status, compared with
less socially active people.
As mentioned, we found no significant ceiling effect on
either subscale of the GO-QOL. This result differs from
those of previous studies, which revealed significant ceiling
effects.9,10 Ponto et al9 reported a ceiling effect and
concluded that visual functioning and self-confidence were
relatively unimpaired in patients with mild stages of GO,
and also concluded that the GO-QOL lacked sensitivity to
discern an effect among mild cases. Similarly, a significant
ceiling effect would limit the applicability of the instru-
ment in measuring improvements in the disease-specific
QOL in GO patients. Our results do not show any signifi-
cant ceiling effects. We conclude that the questionnaire
was able to detect improvements in QOL resulting from
appropriate treatment. Several studies have shown that
GO-QOL scores improved after treatment and that the
questionnaire can provide a good outcome measure.11,12
Future study is needed to address this issue further. We
also found no significant floor effects for either subscale,
and the results were consistent with those of previous
studies.9,10 We concluded that the GO-QOL was able to
assess deterioration in the disease-specific QOL of patients
with GO.
Our study was subject to certain limitations. First, all
patients were recruited through a single academic insti-
tution. These patients had been referred from local hos-
pitals and may have had above-average disease severity.
Thus, the condition of patients in our clinic might differ
from that of patients in the general community settings.
Second, we looked at a large number of unselected pa-
tients. These patients having various degrees of disease
activity and severity were not divided into treated and
untreated patients. QOL might also be influenced by the
actual management (including side effects). Third, the
cross-sectional design of our study did not allow us to
evaluate possible changes in a patient’s GO-QOL scores
over time, or treatment effect. Fourth, we could not
exclude the possibility that the clinical examination might
have influenced patients’ responses to the questionnaire
items. Finally, the objective clinical parameters were
assessed by a single clinician; this consistency would have
improved reliability, but might have introduced systematic
bias.
In conclusion, the Chinese (Taiwan) version of the
GO-QOL is a simple questionnaire that is convenient for
clinical use. The GO-QOL score was strongly correlated with
disease severity and with clinical activity. Our study showed
that the questionnaire is a practical tool that can be used to
evaluate health-related QOL in GO patients.
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